The company, spun off from Glenmark Pharmaceuticals in 2019 to focus on the API business, said its revenue from operations jumped nearly 17 per cent to 5.95 billion rupees, with regulated markets including the U.S., Europe, Latin America and India contributing 80 per cent.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment